Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


METHOD OF MAKING A TRANSGENIC NONHUMAN ANIMAL

Subclass of:

800 - Multicellular living organisms and unmodified parts thereof and related processes

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
800021000METHOD OF MAKING A TRANSGENIC NONHUMAN ANIMAL89
20110179510METHOD FOR CULTURING AVIAN GONOCYTES - A sustained culture of isolated avian gonocytes is provided, as well as a method of making and using the same. A chimeric avian containing an isolated gonocyte and a transgenic avian produced using the chimeric avian are also provided. The cell and method may be employed to make, among other things, transgenic avian that produce a heterologous protein, e.g., a therapeutic protein.07-21-2011
20080244763LEPTIN PROMOTER POLYMORPHISMS AND USES THEREOF - The present invention relates to single nucleotide polymorphisms (SNPs) in the leptin promoter, and to methods for the identification of animals carrying specific alleles of these SNPs that are associated with circulating leptin levels, feed intake, growth rate, body weight, carcass merit and carcass composition. The present invention provides oligonucleotides that can be used as primers and/or probes to amplify and/or detect these SNPs, and provides methods for selecting and grouping animals, in particular bovines, according to genotype.10-02-2008
20100043083Insect chemosensory receptors and methods of use thereof - Methods for controlling insect attraction, as well as inhibiting, preventing and reducing the incidence of insect-borne disease in a subject, are described by inhibiting the expression, activity, dimerization or signaling by gustatory receptors that alter insect responsiveness to carbon dioxide. Methods for identifying agents for effecting the same by interfering with expression, activity, dimerization or signaling by gustatory receptors are also provided.02-18-2010
20120192301METHODS AND COMPOSITIONS FOR GENE CORRECTION - Disclosed herein are methods and compositions for correction and/or mutation of genes associated with Parkinson's Disease as well as clones and animals derived therefrom.07-26-2012
20130061343IN VIVO GENE REGULATION BY THE COMBINATION OF KNOCK-IN-TETO SEQUENCE INTO THE GENOME AND TETRACYCLINE-CONTROLLED TRANS-SUPPRESSOR (TTS) PROTEIN - Disclosed is a FAST (Flexible Accelerated STOP TetO-knockin) system, an efficient method for manipulating gene expression in vivo to rapidly screen animal models of disease. This invention further discloses a single gene targeting event yielding 2 distinct knockin mice—STOP-tetO and tetO knockin—which permit generation of multiple strains with variable expression patterns: 1) knockout, 2) Cre-mediated rescue; 3) tTA-mediated misexpression; 4) tTA-mediated overexpression; and 5) tTS-mediated conditional knockout/knockdown. Using the FAST system, multiple gain- and loss-of-function strains can therefore be generated on a timescale not previously achievable. These strains can then be screened for clinically-relevant abnormalities. The flexibility and broad applicability of the FAST system is demonstrated by targeting several genes encoding proteins implicated in neuropsychiatric disorders: Mlc1, Neuroligin 3, the serotonin 1A receptor, and the serotonin 1B receptor.03-07-2013
20090271884ES Cell-Derived Mice From Diploid Host Embryo Injection - Genetically modified mice and nucleic acid constructs for making the genetically modified mice are described. A first mouse having a gene encoding an activator (such as a Cre recombinase) operably linked to a developmentally-regulated promoter (such as a Nanog promoter) is provided. A second mouse having a toxic responder gene (such as a gene encoding diphtheria toxin A) is provided, where the toxic gene is expressed only in the presence of an activator, Embryos from a mating of the first and the second mouse are provided as host embryos suitable for generating mice from donor cells introduced into the host embryos. Ablating the ICM of a mouse embryo physically, chemically, or genetically is described, as well as making F0 generation mice that are substantially or in full derived from donor cells, employing a host mouse embryo with an ablated or nonproliferating ICM.10-29-2009
20120102583RESISTANCE TO BACTERIAL INFECTION - The present invention provides a method of identifying an animal having a genotype associated with resistance to bacterial infection comprising the steps of: (a) providing a sample from said mammal; (b) determining the alleles at one or more markers of the SAL1 locus to identify the genotype of the marker, wherein said SAL1 locus lies between 54.0 MB to 54.8 MB of chicken Chromosome 5 or an equivalent thereof; and (c) determining whether the genotype is a genotype associated with resistance to bacterial infection.04-26-2012
20110289611RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE - The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.11-24-2011
20110219465Suppression of B-Cell Apoptosis in Transgenic Animals Expressing Humanized Immunoglobulin - The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression. This latter method allows for increased expression and production of the transgene encoded product(s) over the endogenously produced immunoglobulin of the transgenic animal. The invention also provides a novel apoptosis-inhibitor, rabbit bcl-2.09-08-2011
20090288182GENE SILENCING - Methods are disclosed for screening for the occurrence of gene silencing (e.g., post transcriptional gene silencing) in an organism. Also provided are methods for isolating silencing agents so identified.11-19-2009
20100281555METHOD FOR MARKING BIO-INFORMATION INTO GENOME OF ORGANISM AND ORGANISM MARKED WITH THE BIO-INFORMATION - Disclosed herein is a method for marking bio-information into the genome of an organism, an organism marked with inherent bio-information by the method and a method for reading the bio-information. The method is characterized in that inherent bio-information encoded to a DNA sequence or RNA sequence is inserted into genome of organisms through a gene delivery system. Inherent bio-information is inserted into genome of organisms, thus avoiding loss by cell culture or artificial manipulation and being widely used even for organisms whose host-vector system is not provided. Based on these features, the method has the following advantages. First, inherent bio-informtion can be clearly obtained from the organisms themselves, rather than an additional means such as catalogs. Second, when organisms developed through desperate efforts are stolen, they can be tracked down and identified. Third, when serious problems occur by overuse or misuse of organisms, the origin thereof can be clearly determined.11-04-2010
20100138947Method for Producing Stem Cells or Stel Cell-Like Cells from Mammalian Embryos - The present invention relates to methods and compositions for the production and derivation of pluripotent stem cells from embryos or embryo-derived cells and therapeutic uses therefor. In particular, the present invention relates to a method for producing functional stem cells or stem cell-like cells comprising the steps of culturing an embryo or embryo-derived cells in the presence of a demethylation agent and isolating functional pluripotent cells.06-03-2010
20110209231TREATMENT AND PREVENTION OF INFLUENZA - The present invention relates to nucleic acid molecules comprising a double-stranded region, and nucleic acid constructs encoding therfor, that are useful for the treatment and/or prevention of influenza. In particular, the present invention relates to nucleic acid constructs encoding a double stranded RNA molecule(s) that can be used to produce transgenic poultry, for example chickens, such that they are at least less susceptible to an avian influenza infection. Also provided are nucleic acid molecules comprising a double-stranded region that can be used as a therapeutic to treat and/or prevent, for example, avian influenza in poultry.08-25-2011
20080263691Compositions And Methods For Regulating Cardiac Performance - The present invention relates to cardiac performance, in particular to regulating cardiac performance via recombinant troponin I (TnI) protein and nucleic acids encoding recombinant TnI. The present invention provides nucleic acids encoding gain of function TnI proteins (e.g., cTnlA164H), vectors containing such nucleic acids, host cells containing such vectors, transgenic animals carrying a gain of function TnI protein (e.g., a cTnlA164H transgene), and therapeutic agents (e.g., comprising recombinant TnI, TnI analogues, synthetic TnI, or the like) or agents for gene therapy of heart failure or disease for research and therapeutic uses.10-23-2008
20100212040ISOLATION OF LIVING CELLS AND PREPARATION OF CELL LINES BASED ON DETECTION AND QUANTIFICATION OF PRESELECTED CELLULAR RIBONUCLEIC ACID SEQUENCES - The invention is directed to reliable and efficient detection of mRNAs as well as other RNAs in living cells and its use to identify and, if desired, separate cells based on their desired characteristics. Such methods greatly simplify and reduce the time necessary to carry out previously-known procedures, and offers new approaches as well, such as selecting cells that generate a particular protein or antisense oligonucleotide, generating cell lines that express multiple proteins, generating cell lines with knock-out of one or more protein, and others.08-19-2010
20090106853Methods and materials using signaling probes - The present invention relates to methods of isolating cells or generating cell lines using signaling probes that produce a signal upon hybridization to a target sequence. Other methods that utilize the signaling probe include methods of quantifying the level of RNA expression, methods for identifying genetic recombinational events in living cells and methods of generating a transgenic animal using the isolated cells. The invention also provides protease probes. Signaling probes and protease probes that form stem-loop structures, three-arm junction structures, and dumbbell structures are provided.04-23-2009
20100293626METHODS FOR IMPROVEMENT OF BIRTH RATES IN CANIDAE ON SOMATIC CELL NUCLEAR TRANSFER - The present invention relates to a method for increasing the efficiency of offspring production in producing animals belonging to the family Canidae (canines) by somatic cell nuclear transfer. More specifically, relates to a method for increasing the efficiency of production of cloned canines by a method for cloning canines comprising enucleating the oocyte of a canine to prepare an enucleated oocyte, fusing a nuclear donor cell with the enucleated oocyte to prepare a nuclear transfer embryo and transferring the nuclear transfer embryo into the oviduct of a surrogate mother, wherein the nuclear donor cell is cultured in a medium containing a specific cell cycle synchronization-inducing substance such as roscovitine in the preparation thereof. The method enables to clone canines with high efficiency, and thus can contribute to the development of studies in the fields of veterinary medicine, anthropology and medical science such as the propagation of superior canines, the conservation of rare or nearly extinct canines, xenotransplantation and disease animal models.11-18-2010
20110041196miRNA-Regulated Differentiation-Dependent Self-Deleting Cassette - Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3′-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.02-17-2011
20090083873SEQUENCE-SPECIFIC INHIBITION OF SMALL RNA FUNCTION - The present invention relates to the discovery of a method for inhibiting RNA silencing in a target sequence-specific manner. RNA silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide. The invention provides compositions for sequence-specific inactivation of the RISC component of the RNA silencing pathway, and methods of use thereof. The RISC inactivators of the present invention enable a variety of methods for identifying and characterizing miRNAs and siRNAs, RISC-associated factors, and agents capable of modulating RNA silencing. Therapeutic methods and compositions incorporating RISC inactivators and therapeutic agents identified through use of RISC inactivators are also featured.03-26-2009
20110088107COMPOSITIONS AND METHODS FOR DERIVING OR CULTURING PLURIPOTENT CELLS - The invention provides compositions and methods useful for deriving or culturing vertebrate ES cells. Certain inventive methods comprise deriving or culturing vertebrate ES cells using medium that comprises a compound that replaces Klf4 or c-Myc in generating iPS cells. The invention provides NOD ES cells and methods of deriving or culturing them.04-14-2011
20110099649Method for performing genetic modification under a drug-free environment and components thereof - The present invention provides a method and components thereof of performing genetic modification under a drug-free environment. The method comprises the steps of generating a trapped mammalian cell library by trapper constructs (including the element of piggyBac terminal inverted repeats (TIRs)), reporter constructs, and helper constructs (including a sequence of an internal ribosomal entry site (IRES)). The present art allows: (1) to target & identify the silenced loci; (2) to separate genes with low-level expression at certain differentiation stages; (3) to evaluate the efficiency of gene targeting in the silent or repressed loci. The present invention avoids the biased gene targeting observed in the prior arts, and eliminates the needs of introducing antibiotic genes into the host genome which may lead to a potential threat of drifting antibiotic resistant genes into environment.04-28-2011
20120204282METHODS AND COMPOSITIONS FOR TREATING OCCULAR DISORDERS - Disclosed herein are methods and compositions for treating ocular disorders.08-09-2012
20080313754Method for generating hypermutable organisms - Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation.12-18-2008
20120278913Ribozyme Effector Gene in Dengue Fever Transmission and Disease Control - Disclosed are anto-DENV ribozyme based methods and compositions useful in the inhibition and control of all Dengue fever serotypes (designated DENV 1 through 4). A group of anti-DENV Group 1 trans-splicing introns (αDENV-GrpIa) are presented that target DENV-2 NGC genomes in situ. Methods for specifically targeting a highly conserved 5′-3′ cyclization sequence (CS) region that is common to all serotypes of the DENV are provided. The anti-DENV Group 1 trans-splicing introns (αDENV-GrpIa) specifically target two different uracil bases on the positive sense genomic strand. The invention provides an RNA based approach for transgeneic suppression of DENV in transformed mosquitoes using a group of specifically designed introns that trans-splice a new RNA sequence downstream of a targeted site. The aDENV-GrpIs target DENV infected genomes and thus provide a method for inhibiting the spread of Dengue fever. An αDENV-GrpI 9v1 is presented that is designed to be active against all forms of Dengue virus, and to effectively target the DENV-2 NGC genome in a sequence specific manner11-01-2012
20110126306Circular Nucleic Acid Vectors, and Methods for Making and Using the Same - Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are to characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.05-26-2011
20110126305Mutant blue fluorescent protein and method of using the same for fluorescence resonance energy transfer and blue fluorescent fish - The present invention discloses a mutant blue fluorescent protein (BFP) exhibiting, at an aerobic or anaerobic system, larger fluorescent intensity than a BFPvv D7 of SEQ ID NO:2 derived from a wild type BFP, BfgV of SEQ ID NO:1, obtained from 05-26-2011
20090193534In vivo transfection in avians - The present invention provides for methods of producing transgenic avians which may include delivering a heterologous nucleic acid to oviduct tissue of an avian wherein the nucleic acid enters a cell of the oviduct tissue and is expressed.07-30-2009
20110265198Genome editing of a Rosa locus using nucleases - Disclosed herein are methods and compositions for genome editing of a Rosa locus, using fusion proteins comprising a DNA binding domain and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.10-27-2011
20090183269GENE EXPRESSION SYSTEM USING ALTERNATIVE SPLICING IN INSECTS - A polynucleotide expression system is provided that is capable of alternative splicing of RNA transcripts of a polynucleotide sequence to be expressed in an organism.07-16-2009
20120151614VECTOR UTILIZING BORNA DISEASE VIRUS AND USE THEREOF - Disclosed is a viral vector comprising 06-14-2012
20120047589METHOD OF DELIVERY OF NUCLEIC ACIDS TO A DEVELOPING EMBRYO - Methods to introduce genetic material, such as DNA, to embryos, are disclosed. In some embodiments, the method involves preparing the pregnant mother to receive the genetic material into a blood transport vessel which passes to the embryo, avoiding a maternal capillary bed and introducing the material under low pressure so as not to kill the pregnant animal. The effectiveness of the method is such that the nucleic acid has been expressed in all the cells of the embryo and in the postnatal mouse, including the primordial germ cells, thus making the nucleic acid germ line heritable.02-23-2012
20110167508PUFA POLYKETIDE SYNTHASE SYSTEMS AND USES THEREOF - The invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems, to homologues thereof, to isolated nucleic acid molecules and recombinant nucleic acid molecules encoding biologically active domains of such a PUFA PKS system, to genetically modified organisms comprising PUFA PKS systems, to methods of making and using such systems for the production of bioactive molecules of interest, and to novel methods for identifying new bacterial and non-bacterial microorganisms having such a PUFA PKS system.07-07-2011
20120017289RAPID METHOD FOR GENERATING GENE KNOCK DOWN MODEL - The present invention provides a novel method of generating knock down models by electroporation of shRNA construct into the testis. The present invention provides an ethically superior, non-surgical, user friendly rapid method for the generation of permanent lines of shRNA knock down non human vertebrates. This invention is ethically superior as it does not involve any loss of animal life and drastically minimizes the production time and use of animals. Current techniques for making knockout models are cumbersome, require trained personnel, costly infrastructure and require hundreds of eggs collected after killing several females. In contrast, this method neither involves any costly infrastructure nor requires trained personnel. The invention also relates to the quick incorporation of shRNA gene construct into the germline of a species so that shRNA is inheritable. The present invention also generates in a single go a variety of knock down models differentially expressing gene specific shRNA, depending on differential shRNA gene incorporation in native genome of various male germ cells, so that there is no restriction in the choice of the gene knock down.01-19-2012
20120017290Genome editing of a Rosa locus using zinc-finger nucleases - Disclosed herein are methods and compositions for genome editing of a 01-19-2012
20130227720Rationally Designed Meganucleases With Altered Sequence Specificity and DNA-Binding Affinity - Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.08-29-2013
20100205684CHICKEN EMBRYONIC STEM CELL AND METHOD FOR EVALUATION THEREOF - A chicken embryonic stem cell is established, which stably has pluripotency and an ability of being differentiated into a germ cell. For evaluating on whether or not the chicken embryonic stem cell can be applied to genetic modification technique, detection is made on a protein which serves as an indicator of the ability of being differentiated into a germ cell. This provides (i) a chicken embryonic stem cell applicable to genetic modification technique and (ii) a method for evaluation of the chicken embryonic stem cell.08-12-2010
20120174245TRANSPOSITION OF MAIZE AC/DS ELEMENTS IN VERTEBRATES - The present invention is directed to the use of the maize Ac/Ds transposable elements in vertebrates.07-05-2012
20100050281Identification of Genes and Their Products Which Promote Hybrid Vigour or Hybrid Debility and Uses Thereof - The present invention relates to a method of identifying candidate genes and the proteins encoded by them that are useful in the inducement of hybrid vigour, hybrid debility and/or the diagnosis, prognosis and treatment of disease. In particular, the present invention relates to a method for identifying candidate genes capable of producing hybrid vigour or hybrid debility in an animal or plant, comprising the steps of: (i) comparing the mRNA sequence of alleles of candidate genes isolated from an animal or plant which exhibits hybrid vigour or hybrid debility with the nucleotide sequences from the corresponding alleles isolated from the parents of said animal or plant; (ii) identifying mRNA sequence differences in the alleles from said animal or plant which exhibits hybrid vigour or hybrid debility which codes for amino acid sequence variation; and (iii) identifying that the amino acid sequence variation between alleles of the candidate gene in said animal or plant is encoded by mRNA sequences which are located within two or more different exons within the candidate gene.02-25-2010
20120233717METHOD FOR PREPARING A TRANSGENIC ANIMAL OF SIMULTANEOUS MULTIPLE-GENE EXPRESSION - A method for preparing a transgenic animal of simultaneous multiple-gene expression is provided. Additionally, a method for preparing a transgenic embryo, which introduces both phytase gene and human myxovirus resistant gene A into a target embryo, to obtain a transgenic embryo is provided. The transgenic animal of simultaneous multiple-gene expression can be achieved by transplanting the transgenic embryo into the body of a female target animal. A significant advantage of the foregoing methods, among many others, exists in that the simultaneous expression of multiple genes can be achieved in one transgenosis, which provides a convenient mean for the preparation of combined-gene transferred animals etc.09-13-2012
20120266266METHODS OF PRODUCING GENETICALLY-MODIFIED EUKARYOTIC CELLS WITH RATIONALLY-DESIGNED MEGANUCLEASES - Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.10-18-2012
20110239319Use of Endonucleases for Inserting Transgenes Into Safe Harbor Loci - The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention further concerns the use of such endonucleases for inserting transgenes into a cell, tissue or individual.09-29-2011
20110277049PRODUCTION OF CLONED OFFSPRING FROM COOLED CARCASSES - Genetic material is derived from animals post-mortem, and used in nuclear transfer processes to produce cloned embryos and live cloned animals having genetic make-ups identical to the post mortem animals. The method has particular applicability to the management and breeding of livestock, to the production of animals having desired genetic traits, and to the integration of those genetic traits into selective breeding operations.11-10-2011
20100229254METHOD FOR TARGETED CELL ABLATION - The present technology relates to a method for causing cell death. The method comprises the step of genetically manipulating chromosomal DNA of a cell such as by, for example, using a recombinase system, to lose an autosome during cell division and wherein loss of the autosome results in death of the cell. The technology also relates to a method for selective ablation of proliferative cells within a population of cells.09-09-2010
20100169996METHODS AND COMPOSITIONS FOR MODULATING THE SIRNA AND RNA-DIRECTED-DNA METHYLATION PATHWAYS - Methods to identify nucleotide sequences whose expression will enhance resistance to pathogen infection are described, as is use of such nucleotide sequences to enhance resistance with minimal side effects on development.07-01-2010
20080250517Methods - The production of genetically modified animals, in which the genetic modifications are engineered in somatic cells cultured in vitro by gene targeting, is described. Genetically modified cells may then used as nuclear donors to produce, inter alia, live animals. The methods described can also be used to validate loci in animal chromosomes which are suitable sites for transgene addition to cells.10-09-2008
20080222744In vivo transfection in avians - The present invention provides for methods of producing transgenic avians which may include delivering a heterologous nucleic acid to oviduct tissue of an avian wherein the nucleic acid enters a cell of the oviduct tissue and is expressed.09-11-2008
20080222743RNA interference and disease resistance in avians - The invention relates to transgenic avians whose genome contains nucleotide sequences which encode therapeutic polynucleotides that correspond to one or more certain sequences in the genome of an avian pathogen.09-11-2008
20080216185Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines - The disclosure relates generally to stem cell biology and more specifically to genetic manipulation of stem cells. Methods and compositions using recombinational cloning techniques are disclosed which allow the construction and insertion of complex genetic constructs into embryonic and adult stem cells and progenitor cells. The methods disclosed will allow the harvesting of adult stem cells pre-engineered with integration sites to facilitate early passage genetic modification.09-04-2008
20130104253CYTOPLASMIC TRANSFER TO DE-DIFFERENTIATE RECIPIENT CELLS - Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.04-25-2013
20130145488MESOPOROUS SILICA NANOPARTICLES SUITABLE FOR CO-DELIVERY - The invention provides gold-plated mesoporous silicate bodies comprising pores and at least one agent and methods of using those bodies.06-06-2013
20100287638NEURAL TUMOR STEM CELLS AND METHODS OF USE THEREOF - The present invention relates to the discovery that renewable stem cell lines can be derived from tumor cells and can be cultured in vitro. Accordingly, the invention provides neural tumor stem cell lines and cells from such cell lines. Because the cell lines retain characteristics of the tumors from which they are derived, the cells can be used in screening methods for identification of potential therapeutic agents and can be used to identify genetic markers which may be predictive for development of such tumors. Finally, such cells can be used to determine an appropriate therapeutic regimen for a patient suffering from a brain tumor. Cells from a patient's brain tumor can be cultured as described herein to create a cell line, and the relative effectiveness of a therapeutic agent against the cells can be tested to determine which agent or combination of agents is most effective in treating the patient's tumor.11-11-2010
20100319079ISOLATED PROLIFERATING CELLS WITH STEM CELL PROPERTIES FROM ADULT TISSUE OF POIKILOTHERMIC VERTEBRATES, STABLE CELL CULTURES THEREOF, AND METHODS FOR THEIR PREPARATION - A method of preparing adult proliferating cells with stem cell properties includes removing tissue from pronephros or pyloric appendates of an intestine of poikilothermic vertebrates, comminuting removed tissue, cultivating comminuted tissue, and propagating cells persisting in a culture.12-16-2010
20100162423Methods and Systems for Inferring Traits to Breed and Manage Non-Beef Livestock - Methods and systems are provided for managing non-beef livestock subjects in order to maximize their individual potential performance and the value of a product from the non-beef livestock subjects, and to maximize profits obtained in marketing the non-beef livestock subjects. The methods and systems draw an inference of a trait of a non-beef livestock subject by determining the nucleotide occurrence of at least one non-beef livestock SNP that is determined to be associated with the trait. The inference is used in methods of the present invention to establish the economic value of a non-beef livestock subject, to improve profits related to selling beef from a non-beef livestock subject; to manage non-beef livestock subjects, to sort non-beef livestock subjects; to improve the genetics of a non-beef livestock population by selecting and breeding of non-beef livestock subjects, to clone a non-beef livestock subject with a specific trait, to track meat or another commercial product of a non-beef livestock subject; and to diagnose a health condition of a non-beef livestock subject. Certain embodiments of the present invention provide methods, systems, and kits are directed to inferences of a trait related to milk or a dairy product in a livestock subject.06-24-2010
20120036591METHODS FOR MITOCHONDRIAL DNA REPLACEMENT IN OOCYTES - Methods are provided for producing a primate oocyte in vitro. The methods include removing nuclear DNA from a recipient primate oocyte from a first primate in a manner that does not lower levels of maturation promoting factor (MPF) to form an enucleated recipient primate oocyte. The recipient primate oocyte is enucleated using a non-UV-based spindle imaging system. Nuclear genetic material or DNA including chromosomes from a donor primate oocyte arrested at metaphase II from a second primate is isolated in the form of the karyoplast and introduced into the enucleated recipient primate oocyte. Introduction of the chromosomes is performed using a fusogenic agent or electroporation to produce a hybrid oocyte.02-09-2012
20120042401METHOD FOR INTRODUCING MUTANT GENE, GENE HAVING MUTATION INTRODUCED THEREIN, CASSETTE FOR INTRODUCING MUTATION, VECTOR FOR INTRODUCING MUTATION, AND KNOCK-IN NON-HUMAN MAMMALIAN ANIMAL - Disclosed is a method for introducing a mutation into a gene, which comprises the following steps: a homologous recombination step of carrying out the homologous recombination between a target gene into which the mutation is to be introduced and a target recombinant vector, thereby substituting an exon in the target gene into which the mutation is to be introduced by a target DNA sequence in the target recombinant vector; and a mutation introduction step of carrying out the specific recombination between the target DNA sequence in the resulting target recombinant gene and a mutation introduction cassette of a mutation introduction vector carrying a mutated DNA sequence containing a mutant exon by the intervening action of Cre recombinase to substitute the target DNA sequence by the mutated DNA in the mutation introduction cassette, thereby producing a mutation-introduced gene into which the mutant DNA sequence has been introduced. The method enables the production of a knock-in non-human mammalian animal, such as a knock-in mouse, which carries the mutation-introduced gene.02-16-2012
20120066783AAV CAPSID LIBRARY AND AAV CAPSID PROTEINS - Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating a library of recombinant adeno-associated viral capsid proteins are also provided.03-15-2012
20120304323MATERNALLY INDUCED STERILITY IN ANIMALS - The present invention provides Maternal Sterility Constructs (MSC) and methods of producing sterile progeny lacking germ cells. Female animals carrying the MSC transgene will give rise to a sterile generation, as the MSC specifically eliminates Progenitor Germ Cells (PGCs) of her progeny. These females are called lineage ending females. Male animals carrying the MSC transgene, however, give rise to fertile progeny (assuming the male is not derived from an MSC-transgenic female). Thus, MSC transgenic males can be used to propagate the transgenic line. The invention can be advantageously applied to eliminate pest or invasive species, or to provide effective population control and improve culture performance of farmed species, such as fish and shellfish.11-29-2012
20130212725FUSION PROTEINS COMPRISING A DNA-BINDING DOMAIN OF A TAL EFFECTOR PROTEIN AND A NON-SPECIFIC CLEAVAGE DOMAIN OF A RESTRICTION NUCLEASE AND THEIR USE - The present invention relates to a method of modifying a target sequence in the genome of a eukaryotic cell, the method comprising the step: (a) introducing into the cell a fusion protein comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease or a nucleic acid molecule encoding the fusion protein in expressible form, wherein the fusion protein specifically binds within the target sequence and introduces a double strand break within the target sequence. The present invention further relates to the method of the invention, wherein the modification of the target sequence is by homologous recombination with a donor nucleic acid sequence further comprising the step: (b) introducing a nucleic acid molecule into the cell, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence. The present invention also relates to a method of producing a non-human mammal or vertebrate carrying a modified target sequence in its genome. Furthermore, the present invention relates to a fusion protein comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease.08-15-2013
800022000 Involving breeding to produce a double transgenic nonhuman animal 9
20090165156METHOD FOR INCREASING THE SALTWATER TOLERANCE OF A FISH - The present invention relates to a method for obtaining an indication of the saltwater tolerance of a fish, and methods for increasing the saltwater tolerance of a fish. In particular, the invention relates to methods involving biomarkers in the transferrin gene which are correlated with high or low saltwater tolerance.06-25-2009
20110016548CONTROL OF ENDOGENOUS DNMT1 GENE EXPRESSION BY EXOGENOUS BINARY REGULATORY SYSTEMS - Provided are methods for controlling endogenous gene expression comprising control of the DNA methyltransferase (Dnmt1) for modulation of DNA methylation and epigenetic mechanisms. Provided are transcriptional regulatory systems involving multiple (e.g., three) exogenous binary systems, lacI, tetR and Gal4, for reversible up/down regulation of endogenous target genes Provided are lac operator and repressor modifications for improved repression relative to wild type (WT) lac and tet systems. Provided are endogenous Dnmt1 promoter modifications, comprising targeted lac operator sequences that do not significantly alter promoter activity absent repressors, yet show substantially reduced expression of the targeted allele upon lac repressor introduction. The lacO targeted Dnmt1 allele is introducible into the mouse germline, to provide a respective upregulatable transcriptional control system in vivo (e.g., two binary systems, tet operator/tetVP16 and Gal4 binding sequence/Gal4VP16, and ES cell gene targeting experiments are conducted with a Dnmt1 promoter construct combining all three cis elements.01-20-2011
20110185442Method of generating transgenic organisms using transposons - The invention relates to a method for generating a transgenic organism. The invention also relates to a method for detecting and characterizing a genetic mutation in a transgenic organism. The invention further relates to a method for isolating a gene which is correlated with a phenotypic characteristic in a transgenic animal. The invention further relates to a method for isolating an exon in a transgenic animal. The invention also relates to a method for modulating the expression of a gene in an organism.07-28-2011
20090293139DOUBLE-INDUCIBLE GENE ACTIVATION SYSTEM AND ITS APPLICATIONS - A double-inducible system for expressing a transgene, preferably comprising an RU486-inducible system integrated with a CID-inducible system. The invention further comprises a gene expression system for use in in vitro cell culture studies, and a gene expression expression system for use in engineering modified bigenic mice.11-26-2009
20120167242COMPOSITIONS AND METHODS RELATING TO NON-HUMAN ANIMALS MODIFIED TO PROMOTE PRODUCTION OF SELECTED GAMETES - Methods and compositions for producing selected non-human mammalian germ cells and gametes and for making non-human animals using the produced germ cells and gametes are provided by the present invention. Methods of generating a non-human embryo and/or animal derived from donor stem cells, methods of generating chimeric non-human animals having substantially all gametes and/or germ cells derived from the donor stem cells, methods of producing a non-human host embryo lacking functional endogenous germ cells and non-human host embryos incapable of developing endogenous gametes of the present invention are described herein.06-28-2012
20120233718USE OF PON GENE CLUSTER IN PREPARING MEDICAMENT FOR TREATING ATHEROSCLEROSIS - Use of PON gene cluster in preparing medicament for treating atherosclerosis in mammals, wherein the PON gene cluster treat atherosclerosis by promoting stability of atherosclerotic plaque. Method for the developing PON gene cluster transgenic mouse model and use of PON gene cluster in the development of PON gene cluster positive transgenic mouse model with atherosclerosis are also provided.09-13-2012
20080229438Process of making transgenic mammals that produce exogenous proteins in milk and transgenic mammals produced thereby - The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos. The method also includes other procedures to generate transgenic embryos for the further expansion of the transgenic herd, such as the subcloning of transgenic female bovines, the superovulation of transgenic cows and their insemination with semen from a non-transgenic or a transgenic male bovine, and the superovulation of non-transgenic cows and their insemination with semen from a transgenic male bovine. Afterwards, transgenic embryos give rise to transgenic cattle that produce human growth hormone in huge amounts in their milk, from which the hormone is completely purified and analysed to fulfill all the requirements for the manufacture of a pure biopharmaceutical product.09-18-2008
20100223687COMPOSITIONS AND METHODS FOR DIAGNOSIS OF GENETIC SUSCEPTIBILITY, RESISTANCE, OR TOLERANCE TO INFECTION BY MYCOBACTERIA AND BOVINE PARATUBERCULOSIS - Provided are methods for determining resistance or tolerance of a subject to 09-02-2010
20110277050SYSTEM AND METHODS TO CONTROL TRANSGENE EXPRESSION - Embodiments of the present invention describe a novel and versatile inducible binary expression system (the ‘Q system’) and methods for controlling transgene expression in vitro and in vivo, for lineage tracing, for genetic mosaic analysis and for determining gene function.11-10-2011
800023000 Via retrovirus 1
20120096573Process for Generating Transgenic Animals Using Recombinant Lentiviruses - A process for generating transgenic animals using recombinant lentiviruses. The process comprises injecting recombinant lentiviruses into the interstituim of the testis of a male to produce mature spermatozoa within a few days. The male with transgene expressing lentivirus is mated with a female, forming a progeny carrying the transgene.04-19-2012
800024000 Via microinjection of a nucleus into an embryo, egg cell, or embryonic cell 15
20090055945Method for Producing Nuclear-Transplanted Egg - It is intended to provide a method for improving a development rate in a somatic nuclear transplantation technique or an artificial insemination technique using a spermatid. The method is a method for producing a nuclear-transplanted egg comprising the steps of transplanting a nucleus of a donor cell into an egg, and treating the nuclear-transplanted egg with an anti-methylating agent.02-26-2009
20090007285METHODS FOR CORRECTING MITOTIC SPINDLE DEFECTS AND OPTIMIZING PREIMPLANTATION EMBRYONIC DEVELOPMENTAL RATES ASSOCIATED WITH SOMATIC CELL NUCLEAR TRANSFER IN ANIMALS - The present invention is directed to various methodologies to make NT a practical procedure for animals, specifically, primates including human and non-human primates. Furthermore, the methods and molecular components provided by the present invention provide a practical means for producing embryos with desired characteristics. In a specific embodiment, the methodology of the present invention comprises introducing nuclei having desired characteristics along with one or more molecular components into an enucleated egg, thus creating a nuclear transfer construct, culturing the egg to produce a viable embryo, transferring the embryo to the oviducts of a female, and producing a cloned animal.01-01-2009
20090089889Neuromedin u receptor subtype 1 deficient transgenic mice and uses thereof - Transgenic mice that have been engineered to be deficient in the gene encoding the neuromedin receptor subtype 1 gene. Such mice are useful in screening for receptor subtype-specific agonists and antagonists.04-02-2009
20090138979MANIPULATING SP1 ACTIVITY TO IMPROVE THERAPEUTIC CLONING - The observed over-expression of Sp1 target genes has inspired inventors to formulate a specific strategy for correcting many gene expression defects, and thus improve clone development. The invention is based on the belief that manipulating Sp1 activity can improve cloning. Inventors believe that cloning is inefficient in large part because of the continued expression of Sp1 target genes in the early cloned embryos, which causes clones to be very unlike normal embryos, and so makes them very unhealthy. Inventors propose that if over-expression of Sp1 target genes is prevented in early stage clones, this would greatly improve cloning efficiency by making the cloned embryos healthy again.05-28-2009
20080263692METHODS FOR CORRECTING MITOTIC SPINDLE DEFECTS ASSOCIATED WITH SOMATIC CELL NUCLEAR TRANSFER IN ANIMALS - The present invention is directed to various methodologies to make NT a practical procedure for animals, specifically, primates including human and nonhuman primates. Furthermore, the methods and molecular components provided by the present invention provide a practical means for producing embryos with desired characteristics. In a specific embodiment, we methodology of the present invention comprises introducing nuclei having desired characteristics along with one or more molecular components into an egg, culturing the egg to produce a viable embryo, transferring the embryo to the oviducts of a female, and producing a cloned animal.10-23-2008
20100083393METHOD OF CONSTRUCTING CLONE MAMMAL - The present invention provides a method of producing a cloned mammal, which uses a mammalian natural killer T cell as a donor cell, a cloned mammal obtained by the method, a method of obtaining an ES cell from the embryo of the cloned animal and an ES cell obtained by the method.04-01-2010
20090031437Method of constructing nucleus-implanted egg, parthenogenetic embryo and parthenogenetic mammal - The present invention is to provide a method for constructing a nucleus-implanted egg, a parthenogenetic embryo and for producing a parthenogenetic mammal each having 2 haploid genome sets originating in mammarian ova, and provides methods of constructing a nucleus-implanted egg having a haploid genome set derived from ng ovum and a haploid genome set from fg ovum, a parthenogenetic embryo and a parthenogenetic mammal, which includes the steps of (1) introducing a primitive ovarian follicle egg (ng ovum) into a nucleus-deleted egg in a germinal vesicle stage (GV stage egg) and then developing them to MII phase (second meiosis metaphase) by in vitro maturing and culturing to prepare a first nucleus-implanted egg, and (2) extracting MII phase chromosome from said first nucleus-implanted egg and introducing it into other MII phase egg (fg ovum) to prepare a second nucleus-implanted egg, wherein ovum from which an imprinted gene that undergoes gene modification posteriori during the generation of sperm is deleted is used as the ng ovum or fg ovum.01-29-2009
20100064380PLURIPOTENT CELLS FROM THE MAMMALIAN LATE EPIBLAST LAYER - This invention relates to the isolation and propagation of pluripotent cells isolated from the mammalian late epiblast layer, termed Epiblast Stem Cells' (EpiSCs). These cells are useful in a range of applications, including the generation of transgenic animal species.03-11-2010
20110041197Promoter-Regulated Differentiation-Dependent Self-Deleting Cassette - Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3′-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.02-17-2011
20090133140Injecting Drosophila Embryos - The present invention provides systems that allow reliable multiplexed transformation of 05-21-2009
20080301828METHOD OF PRODUCING CLONED ANIMALS BY DEMECOLCINE TREATMENT - Provided is a method of effectively producing a cloned animal by demecolcine treatment. A conventional method of producing a nuclear transfer embryo of an animal further includes demecolcine treatment after activation of a fused oocyte. Moreover, the method of producing a cloned animal is characterized by culturing the nuclear transfer embryo in vitro and transferring the embryo in vivo.12-04-2008
20100235937PRODUCTION OF TRANSGENIC AVIAN ORGANISMS EMPLOYING EMBRYONIC STEM CELLS - Method of culturing embryonic stem (ES) cells of avian origin includes the steps of: a) suspending ES cells originating from the blastoderm disk of fertilized un-incubated avian egg(s) in a basal culture medium supplemented with: insulin-like growth factor-1 (IGF-1) and ciliary neurotrophic factor (CNTF); and animal serum; and, optionally, at least one growth factor selected from among interleukin 6 (II-6), interleukin 6 receptor (II-6R), stem cell factor (SCF), fibroblast growth factor (FGF), leukemia inhibitory factor (LIF), interleukin 11 (II-11), oncostatin and/or cardiotrophin;09-16-2010
20080222745Colcemid-Treatment of Oocytes to enhance Nuclear Transfer Cloning - Disclosed herein are methods of generating a recipient cytoplast for nuclear cloning with improved developmental capacity. These methods involve the in vitro maturation of an oocyte from a non-human mammal to the pre-MII stage and treatment of the oocyte with a microtubule-inhibiting agent prior to enucleation. The oocyte used to generate the recipient cytoplast can be obtained from a pre-adult or adult non-human mammal. The methods further provide for utilizing the generated recipient cytoplast for nuclear transfer, such as deriving a nuclear transfer embryo or offspring.09-11-2008
20100293627METHOD FOR CLONING ANIMALS WITH TARGETTED GENETIC ALTERATIONS BY TRANSFER OF LONG-TERM CULTURED MALE OR FEMALE SOMATIC CELL NUCLEI, COMPRISING ARTIFICIALLY-INDUCED GENETIC ALTERATIONS, TO ENUCLEATED RECIPIENT CELLS - An improved method of nuclear transfer employing long-term cultured somatic cells as the donor cells and enucleated oocytes as the recipient cells to produce dividing cybrids. Such cybrids are useful for developing viable animals clones when nurtured in a suitable host environment.11-18-2010
20100122364METHOD OF CONSTRUCTING NUCLEUS-IMPLANTED EGG, PARTHENOGENETIC EMBRYO AND PARTHENOGENETIC MAMMAL - Disclosed is a method for constructing a nucleus-implanted egg, a parthenogenetic embryo and for producing a parthenogenetic mammal each having 2 haploid genome sets originating in mammalian ova, and provides methods of constructing a nucleus-implanted egg having a haploid genome set derived from primitive ovarian follicle egg (ng ovum) and a haploid genome set from MII phase (second meiosis metaphase) egg (fg ovum), a parthenogenetic embryo and a parthenogenetic mammal, including steps (1) introducing ng ovum into a nucleus-deleted deleted germinal vesicle stage (GV) egg, developing the obtained egg to MII phase by in vitro maturing and culturing to prepare a first nucleus-implanted egg, and (2) extracting MII phase chromosome from the first nucleus-implanted egg and introducing it into other fg ovum to prepare a second nucleus-implanted egg, wherein a ng or fg ovum from which an imprinted gene undergoing epigenetic modification during sperm generation is used.05-13-2010
800025000 Via microinjection of DNA into an embryo, egg cell, or embryonic cell 6
20100205685Injecting Drosophila Embryos - The present invention provides systems that allow reliable multiplexed transformation of 08-12-2010
20100146655METHODS AND MATERIALS FOR PRODUCING TRANSGENIC ANIMALS - Transgenic artiodactyls are described as well as methods of making and using such artiodactyls.06-10-2010
20100024050PUFA POLYKETIDE SYNTHASE SYSTEMS AND USES THEREOF - The invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems isolated from or derived from non-bacterial organisms, to homologues thereof, to isolated nucleic acid molecules and recombinant nucleic acid molecules encoding biologically active domains of such a PUFA PKS system, to genetically modified organisms comprising PUFA PKS systems, to methods of making and using such systems for the production of bioactive molecules of interest, and to novel methods for identifying new bacterial and non-bacterial microorganisms having such a PUFA PKS system.01-28-2010
20110047635METHODS AND COMPOSITIONS FOR TRANSPOSON-MEDIATED TRANSGENESIS - Methods and compositions for transposon-mediated transgenesis are provided herein. In some embodiments, methods are provided for generating a transgenic embryo containing a piggyBac-like transposon. In some embodiments, such methods can include: contacting a nucleic acid containing a transgene flanked by two terminal repeats with one of the group consisting of: a piggyBac-like transposase polypeptide and a nucleotide sequence encoding a piggyBac-like transposase to form a mixture; contacting the mixture with a sperm to form a composition; and introducing the composition into an unfertilized oocyte to form a transgenic embryo, wherein the piggyBac-like transposase catalyzes the integration of the transgene into the genome of the embryo. In some embodiments, the piggyBac-like transposase can be encoded by a nucleotide sequence on the same nucleic acid containing the transgene. In some embodiments, the nucleic acid encoding the piggyBac-like transposase can be an mRNA.02-24-2011
20110061120SELF-CLEAVING RIBOZYMES AND USES THEREOF - In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.03-10-2011
20120030783RATIONALLY DESIGNED MEGANUCLEASES WITH ALTERED SEQUENCE SPECIFICITY AND DNA-BINDING AFFINITY - Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.02-02-2012

Patent applications in class METHOD OF MAKING A TRANSGENIC NONHUMAN ANIMAL

Patent applications in all subclasses METHOD OF MAKING A TRANSGENIC NONHUMAN ANIMAL